Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG‐positive prostate cancer

Abstract excerpt

Gene fusions between prostate-specific, androgen responsive TMPRSS2 gene and oncogenic ETS factors, such as ERG, occur in up to 50% of all prostate cancers. We recently defined a gene signature that was characteristic to prostate cancers with ERG activation. This suggested epigenetic reprogramming, such as upregulation of histone deactylase 1 (HDAC1) gene and downregulation of its target genes. We then...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histone Deacetylase Inhibitors Research
• Share to Prostate Cancer Treatment and Research
• Share to Ubiquitin and proteasome pathways